SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma India reports net loss of Rs 8.14 crore in Q1

11 Aug 2012 Evaluate

AstraZeneca Pharma India has reported results for first quarter ended June 30, 2012.

On standalone basis, the company has reported a net loss of Rs 8.14 crore for the quarter ended June 30, 2012 against net profit of Rs 16.74 crore for the corresponding period last fiscal. Total income decreased by 28.68% at Rs 99.12 crore during the quarter under review from Rs 138.98 crore in the year-ago period.

AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.

Astrazeneca Pharma Share Price

8586.00 179.40 (2.13%)
22-Jun-2026 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1863.30
Dr. Reddys Lab 1293.55
Cipla 1415.25
Zydus Lifesciences 1079.80
Lupin 2342.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: